ConductScience.org, home

Paper779704

Potentiation by metyrosine of thioridazine effects in chronic schizophrenics. A long-term trial using double-blind crossover technique.

Wålinder J and 3 others. Arch Gen Psychiatry, 1976. Cited by 40 papers, by iCite.

Cite this record

ConductScience Library. Potentiation by metyrosine of thioridazine effects in chronic schizophrenics. A long-term trial using double-blind crossover technique. Papers, record 779704. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/779704

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Potentiation by metyrosine of thioridazine effects in chronic schizophrenics. A long-term trial using double-blind crossover technique.
PubMed
Journal
Arch Gen Psychiatry
PubMed
Year
1976
PubMed
Publication types
Clinical Trial, Controlled Clinical Trial, Journal Article
PubMed
Citations, by iCite
40
iCite
Relative citation ratio, by iCite
1.77
iCite
Revised in PubMed
2019-07-17
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wålinder JJ
2Skott AA
3Carlsson AA
4Roos BEB E

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
MethyltyrosinesMajor topic
SchizophreniaMajor topic
ThioridazineMajor topic
Aged
Chronic Disease
Clinical Trials as Topic
Drug Synergism
Drug Therapy, Combination
Female
Homovanillic Acid
Humans
Hydroxyindoleacetic Acid
Male
Middle Aged

Source PubMed

Download CSV of topics

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 40 citations.

PMIDTitleJournalYearIn PapersSource
39562449The Use of Event-Related Potentials in the Study of Schizophrenia: An Overview.Adv Neurobiol2024https://conductscience.org/library/papers/39562449PubMed
38731862Tyrosine Hydroxylase Inhibitors and Dopamine Receptor Agonists Combination Therapy for Parkinson's Disease.Int J Mol Sci2024https://conductscience.org/library/papers/38731862PubMed
25586400Glutamate and dopamine in schizophrenia: an update for the 21st century.J Psychopharmacol2015https://conductscience.org/library/papers/25586400PubMed
17636691Thioridazine for schizophrenia.Cochrane Database Syst Rev2007https://conductscience.org/library/papers/17636691PubMed
7857586Persistent psychosis after reduction in pre- and post-synaptic dopaminergic function.J Neural Transm Gen Sect1994https://conductscience.org/library/papers/7857586PubMed
6441943Effects of (-)3-PPP on acquisition and retention of a conditioned avoidance response in the rat.Psychopharmacology (Berl)1984https://conductscience.org/library/papers/6441943PubMed
6149256Antipsychotic treatment with alpha-methyltyrosine in combination with thioridazine: prolactin response and interaction with dopaminergic precursor pools.J Neural Transm1984https://conductscience.org/library/papers/6149256PubMed
2871578Acute dystonia induced by neuroleptic drugs.Psychopharmacology (Berl)1986https://conductscience.org/library/papers/2871578PubMed
1358119Pharmacologic properties of (-)-3PPP (preclamol) in man.J Neural Transm Gen Sect1992https://conductscience.org/library/papers/1358119PubMed
703854Inhibition of the in vivo biosynthesis and changes of catecholamine levels in rat brain after alpha-methyl-p-tyrosine; time- and dose-response relationships.Naunyn Schmiedebergs Arch Pharmacol1978https://conductscience.org/library/papers/703854PubMed
438807Dose-dependent pharmacokinetics of alpha-methyl-p-tyrosine (alpha-MT) and comparison of catecholamine turnover rates after two doses of alpha-MT.J Neural Transm1979https://conductscience.org/library/papers/438807PubMed
417365Effect of baclofen on tardive dyskinesia.Psychopharmacology (Berl)1978https://conductscience.org/library/papers/417365PubMed
104344Tolerance to alpha-methyl-p-tyrosine in rats: studies on the antagonism of amphetamine-induced motor activity and excitatory behaviour.Psychopharmacology (Berl)1978https://conductscience.org/library/papers/104344PubMed
41188Antidepressant and antipsychotic agents.Naturwissenschaften1979https://conductscience.org/library/papers/41188PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/779704

GET https://conductscience.org/api/papers/v1/779704/authors